Prognosis and outcomes of lymphocyte-predominant Hodgkin's lymphoma
Grace Suh and Anas Younes*
Correspondence *Department of Lymphoma and Myeloma, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
Email ayounes@mdanderson.org
This article has no abstract so we have provided the first paragraph of the full text.
LPHL is rare, accounting for approximately 400–500 new cases of Hodgkin's lymphoma per year in the US. Owing to its rarity, most information regarding therapy and prognosis is largely obtained retrospectively, from single institution reports and pooled data from multicenter analyses. Furthermore, although LPHL is more similar in pathological and biological features to follicular, B-cell non-Hodgkin's lymphoma than to cHL, patients with LPHL were, until recently, treated in the same manner as those with cHL.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.